Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 25, 1997

View Archived Issues

New NMDA antagonists from Merck KGaA

Angiogenesis inhibitors described by Janssen

Novo Nordisk presents potassium channel openers/blockers

Novartis prepares protein tyrosine kinase inhibitors

Short-term efficacy and safety of T-20 in HIV infection

Oxandrolone + glutamine for HIV-associated wasting

AIDS dementia reversed by highly active antiretroviral therapy

Spotlight on bisphosphonates in osteoporosis

LY-303366: efficacy in rabbits with invasive pulmonary aspergillosis

Nonsteroidal inhibitors of steroid C17,20-lyase developed at Yamanouchi

Yamanouchi develops potent and selective PDE IV inhibitors

Synaptic identifies potent, selective alpha1a-adrenoceptor antagonist

Osteoporosis indication for tiludronate dropped

Colonic prokinetic agent discovered by Janssen

Irbesartan introduced in first markets

Crinone approved for marketing in Germany

Labeling changes for Seldane products

Twinrix approved for marketing in Canada

FDA grants final marketing approval for Corlopam

L-Arginine for liver ischemia/reperfusion injury and transplantation

FTY-720: novel immunosuppressant for combination therapy

Draxis Health subsidiary initiates phase I testing of DVT diagnostic agent

rNAPc2 completes phase Ia testing with positive results

Phase III trial of Neuprex in meningococcemia continues; pilot trial in CF begins

Positive efficacy results obtained in phase II trial of ALX1-11; phase III trials will begin soon

Alliance and Schering AG sign agreement for Imagent US

Popular Stories

News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Chinese biotechs gain leverage as partners in dealmaking
BioWorld
China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
Bio Korea 2026 kicks off with spotlight on oligonucleotides
BioWorld
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
Roche identifies new TREM2 agonists
BioWorld Science
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have prepared and tested new compounds acting as triggering receptor expressed on myeloid cells 2 (TREM2)...
Plasticity, properly parsed, provides psychiatric platform
BioWorld
If Benjamin Braddock, of The Graduate fame, were a young neuroscientist in the 21st century instead of a liberal arts graduate in 1967, the advice he received...